15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 16 firms covering Gilead Sciences Inc, 13 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $123.00 to $180.00, a moderate spread. The average target of $156.87 sits 7% above the current $146.60. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $2.19 next quarter toward $9.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS16 ratings
Strong Buy
Strong Buy00%
Buy1381%
Hold319%
Sell00%
Strong Sell00%
Based on 16 analysts giving stock ratings to Gilead Sciences Inc.
As of Sep, 13 of 16 firms rate GILD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GILD EPS & revenue forecast
EPS · NEXT QUARTER
$2.19
Range $1.92 – $3.13 · 20 analysts · +18% YoY
Next period, 20 analysts expect Gilead Sciences Inc to earn $2.19 a share (range $1.92 – $3.13), versus $1.86 a year earlier. Full-year consensus is $-0.43, growing to $9.89 the year after.
REVENUE · NEXT QUARTER
$8.1B
Range $7.9B – $8.6B · 20 analysts · +3% YoY
Revenue is expected to reach $8.1B (range $7.9B – $8.6B), +2.6% year-over-year. Full-year consensus is $30.7B, rising to $32.7B next year.
Top analysts covering Gilead Sciences Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GILD.
#1
Joseph Stringer
Needham · Rank #195
Buy
$170.00+16.0% to target
Overall win rate
36%
+ Follow
#2
Matthew Harrison
Morgan Stanley · Rank #300
Buy
$165.00+12.6% to target
Overall win rate
45%
+ Follow
#3
Daina Graybosch
Leerink Partners · Rank #304
Hold
$127.00-13.4% to target
Overall win rate
40%
+ Follow
#4
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$162.00+10.5% to target
Overall win rate
47%
+ Follow
#5
Brian Abrahams
RBC Capital · Rank #371
Hold
$123.00-16.1% to target
Overall win rate
28%
+ Follow
GILD stock forecast FAQ
What is GILD's average 12-month price target?+
The 15 analysts with a live target average $156.87 for Gilead Sciences Inc over the next 12 months, ranging from a $180.00 high to a $123.00 low.
Is GILD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 16 analyst ratings, 13 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GILD?+
The Street-high target is $180.00 (Jefferies), and the Street-low is $123.00 (RBC Capital). The average of all 15 active targets is $156.87.
How many Wall Street analysts cover GILD?+
16 analysts have an active rating on Gilead Sciences Inc, and 15 firms carry a live 12-month price target.
Who is the most accurate analyst covering GILD?+
Among analysts who currently cover GILD, Joseph Stringer of Needham has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $170.00 target.
What is Gilead Sciences Inc's projected EPS for next quarter?+
The consensus estimate is $2.19 per share (range $1.92 – $3.13) across 20 analysts. Full-year EPS is projected at $-0.43, rising to $9.89 the following year.
How much revenue is Gilead Sciences Inc expected to report next quarter?+
Consensus revenue is $8.1B (range $7.9B – $8.6B). Full-year revenue is projected at $30.7B, growing to $32.7B next year.
Have analysts been upgrading or downgrading GILD lately?+
As of Sep, 13 of 16 firms rate GILD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GILD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
